SUT BEZI SARATONINI ERTA TASHXISLASH VA DAVOLASHDA IMMUNOONKOLOGIK TEKSHIRUVLARNING AHAMIYATI
Ключевые слова:
sut bezi saratoni, immunoonkologiya, biomarkerlar, HER2, PD-L1Аннотация
Mazkur maqolada sut bezi saratonini erta aniqlash va davolash samaradorligini oshirishda immunoonkologik tekshiruvlar, xususan interleykinlar (IL-6 va IL-10) ning diagnostik ahamiyati kompleks tahlil qilinadi. Tadqiqotning asosiy maqsadi — an’anaviy biomarkerlar (HER2, PD-L1, gormonal retseptorlar) bilan bir qatorda interleykinlarni qo‘llash orqali kasallikni erta aniqlash, prognoz qilish va individual davolash strategiyasini takomillashtirishdan iborat. Tadqiqot jarayonida IL-6 va IL-10 ning biologik roli, o‘sma jarayonlari bilan bog‘liqligi hamda klinik-diagnostik ahamiyati baholandi. Natijalar shuni ko‘rsatdiki, IL-6 darajasining oshishi o‘sma proliferatsiyasi va agressivligi bilan bog‘liq bo‘lsa, IL-10 immunosupressiv muhitni shakllantirib, kasallik prognoziga ta’sir ko‘rsatadi. Interleykinlarni aniqlash diagnostik aniqlikni oshirib, kasallikni erta bosqichda aniqlash imkonini beradi.
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
2. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science, 235(4785), 177–182.
3. Иванов, А. П., Петров, С. Н., & Кузнецов, В. И. (2021). Иммуногистохимические маркеры в диагностике рака молочной железы. Онкология и радиология, 45(3), 112–118.
4. Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., … Brown, P. O. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752.
5. Karimov, B. T., & Yusupova, D. A. (2023). Sut bezi saratonida multimodal diagnostika yondashuvi. O‘zbekiston tibbiyot jurnali, 1(1), 33–41.
6. Jensen, E. V., & Jordan, V. C. (1970). The estrogen receptor: A historical perspective. Endocrine Reviews, 21(2), 127–145.
7. Honjo, T. (1992). Programmed cell death and immunoregulation. Immunological Reviews, 129(1), 5–25.
8. Allison, J. P. (2010). Immune checkpoint blockade in cancer therapy. Annual Review of Medicine, 61, 141–152.
9. Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., … Emens, L. A. (2020). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine, 379(22), 2108–2121.
10. Рустамова, М. Ш. (2022). Современные методы диагностики рака молочной железы. Медицинский журнал Узбекистана, 2(4), 55–61.
11. Mirziyoyev, S. M. (2020). O‘zbekiston Respublikasida sog‘liqni saqlash tizimini rivojlantirish strategiyasi. Toshkent: O‘zbekiston nashriyoti, 88–95.
